Why the study?
Recent technological developments in CCTA provide novel markers beyond obstructive CAD quantification that may improve risk stratification and enable bespoke management across various cardiac settings.
Emerging CCTA markers such as epicardial adipose tissue, late iodine enhancement, and plaque characterization offer additional risk stratification beyond simple quantification of obstructive CAD.
Answers are grounded in this paper and cite their sources.
May refine CCTA-based risk stratification beyond stenosis; leaves open whether integration into precision medicine improves outcomes.
Nowadays, coronary computed tomography angiography (CCTA) has a role of paramount importance in the diagnostic algorithm of ischemic heart disease (IHD), both in stable coronary artery disease (CAD) and acute chest pain. Alongside the quantification of obstructive coronary artery disease, the recent technologic developments in CCTA provide additional relevant information that can be considered as "novel markers" for risk stratification in different settings, including ischemic heart disease, atrial fibrillation, and myocardial inflammation. These markers include: (i) epicardial adipose tissue (EAT), associated with plaque development and the occurrence of arrhythmias; (ii) late iodine enhancement (LIE), which allows the identification of myocardial fibrosis; and (iii) plaque characterization, which provides data about plaque vulnerability. In the precision medicine era, these emerging markers should be integrated into CCTA evaluation to allow for the bespoke interventional and pharmacological management of each patient.
No takes yet. Share an insight, caveat, or question.
Tonet et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: